<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-055663</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Clinical efficacy of sildenafil in patients with pulmonary hypertension in functional class II or III</dc:title>
<dc:description xml:lang="en">Objective: To assess the efficacy of treatment with sildenafil monotherapy in patients with pulmonary hypertension.         Patients and methods: An observational study was undertaken in 11 patients with pulmonary hypertension in functional class II or III who received treatment with sildenafil (150 mg/day). Seven of the patients had inoperable chronic thromboembolic pulmonary hypertension and 4 had pulmonary arterial hypertension. To assess treatment response, the following parameters were assessed during follow-up at 3, 6, and 12 months: exercise tolerance in the 6-minute walk test, change in functional class, and systolic pulmonary arterial pressure measured by echocardiography.         Results: We observed a significant improvement in exercise tolerance, as shown by increased 6-minute walk distance after 3, 6, and 12 months of treatment (increases of 20, 67, and 95 m, respectively). All patients showed an improvement in functional class. The results of echocardiography did not reveal statistically significant differences in systolic pulmonary arterial pressure between baseline and 6 or 12 months of treatment. No significant adverse effects were observed, although sildenafil treatment was suspended in 1 patient due to persistent headache.         Conclusions: The results of this study confirm that sildenafil is an effective drug for the management of pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension both in the short term and medium to long term, and that the drug is well tolerated and shows few side effects</dc:description>
<dc:creator>Souto Alonso, Ana</dc:creator>
<dc:creator>Blanco Aparicio, Marina</dc:creator>
<dc:creator>Raposo Sonnenfeld, Inés</dc:creator>
<dc:creator>Otero González, Isabel</dc:creator>
<dc:creator>Verea Hernando, Héctor</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Valorar la eficacia del tratamiento con sildenafilo en monoterapia en pacientes con hipertensión pulmonar (HP).         Pacientes y métodos: Se ha realizado un estudio observacional de 11 pacientes con HP en clases funcionales II y III, a quienes se administró tratamiento con sildenafilo (150 mg/día). Siete presentaban HP tromboembólica crónica y no quirúrgica y 4, hipertensión arterial pulmonar. Para valorar la respuesta analizamos a los 3, 6 y 12 meses los siguientes parámetros: tolerancia al esfuerzo mediante el test de la marcha de 6 min, cambio de clase funcional y ecocardiograma para valorar la presión sistólica en la arteria pulmonar.         Resultados: Encontramos una mejoría significativa de la tolerancia al esfuerzo, con un incremento de la distancia caminada en 6 min, a los 3, 6 y 12 meses de tratamiento (+20, +67 y +95 m, respectivamente). Todos los pacientes mejoraron de clase funcional. El seguimiento ecocardiográfico no mostró diferencias estadísticamente significativas entre los valores basal y a los 6 y 12 meses de tratamiento de la presión sistólica en la arteria pulmonar. No observamos efectos adversos significativos, aun cuando se retiró el tratamiento con sildenafilo en un paciente por cefalea persistente.         Conclusiones: Los hallazgos de este estudio confirman que el sildenafilo es un fármaco eficaz para el manejo de la hipertensión arterial pulmonar y la HP tromboembólica crónica y no quirúrgica, tanto a corto como a medio-largo plazo, con buena tolerancia y escasos efectos secundarios</dc:description>
<dc:source>Arch Bronconeumol;43(5): 272-276, mayo 2007. ilus, tab</dc:source>
<dc:identifier>ibc-055663</dc:identifier>
<dc:title xml:lang="es">Hipertensión pulmonar: eficacia clínica del sildenafilo en clases funcionales II-III</dc:title>
<dc:subject>^d29623</dc:subject>
<dc:subject>^d28625</dc:subject>
<dc:subject>^d7155^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d10919^s22073</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d28563</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d18001</dc:subject>
<dc:type>article</dc:type>
<dc:date>200705</dc:date>
</metadata>
</record>
</ibecs-document>
